Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-

Chemotherapy-Induced Toxicity

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 4 / ApprovedActive

BBB

75/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 95/ 100

Competitive context

62 Active assets in the Chemotherapy-Induced Toxicity cohort.

Asset / Sponsor	Phase	Rating
Dexasone Instituto do Cancer do Estado de São Paulo	Phase 4	A
Palonosetron Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 4	A
HR20013 Fujian Shengdi Pharmaceutical Co., Ltd.	Phase 3	BB
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 4	BB
Netupitant Instituto Brasileiro de Controle do Cancer	Phase 3	BB

View all 50 →

Same molecule, other indications

Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:

uterine cancerDormant

Indicative · Phase 4

68 / 100

View asset →

breast cancerActive

Indicative · Phase 4

67 / 100

View asset →

hematopoietic and lymphoid system neoplasmDormant

Indicative · Phase 3

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →